Re-evaluating the Duration in Children of TB Treatment

Current tuberculosis (TB) treatment is effective (works well), but it takes a long time to cure TB. This study will evaluate if TB treatment with a higher dose of rifampicin, one of the TB medicines, and shorter TB treatment duration is as effective and safe as the standard, TB treatment (with the usual rifampicin dose and usual duration). This study hopes to find a better shorter treatment that works as well as the current treatment (standard of care). This could benefit children worldwide who are getting TB treatment. Children 3 months to less than 10 years of age who have drug-susceptible TB (can be successfully treated with standard TB medicines) are eligible for this study.

NCT Number	NCT07656012
Lead Sponsor	University of Wisconsin, Madison Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	Tuberculosis
Enrollment	230 participants
Start Date	2026-09
Primary Completion	2030-09 (estimated)
Study Completion	2030-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-18